GHK-Cu

Plain-English version: GHK-Cu is a very small molecule made of three amino acids — glycine, histidine, and lysine — locked onto a single copper atom. Your body produces it naturally, and it appears to act like a "repair signal" that helps skin and other tissues rebuild. In skincare, you will see it on ingredient labels as "copper peptide," "copper tripeptide-1," or "GHK-Cu."

It was discovered in the 1970s when Dr. Loren Pickart observed that albumin (a blood protein) from young donors could prompt older liver tissue to behave in a more youthful way. The active factor was isolated and identified as the tripeptide GHK, which binds copper with high affinity — hence "GHK-Cu."

GHK-Cu is often described as declining with age: plasma concentrations are frequently cited as roughly 200 ng/mL around age 20, falling to about 80 ng/mL by age 60. This figure is widely repeated in Pickart's review articles^[1] and has led to the hypothesis that falling GHK-Cu contributes to slower tissue repair with age. Treat it as a hypothesis supported by review-level literature, not a settled clinical fact.

The gene-modulation claim, stated honestly: You will read everywhere that GHK-Cu "affects roughly 4,000 genes" — about 6% of the human genome. That number comes from an analysis of the Broad Institute's Connectivity Map (CMAP) database reported in Pickart's 2015 and 2018 review articles.^[1][2] It is a bioinformatics/review claim describing a pattern of gene-expression changes, not the result of an independent controlled human trial. The pattern favors repair — genes for collagen synthesis, antioxidant defense, and tissue remodeling shift up, while some inflammation and tissue-breakdown genes shift down.

Regulatory reality: GHK-Cu is not FDA-approved as a drug for any therapeutic use. It lives in two lanes. As a topical cosmetic ingredient (Copper Tripeptide-1), it is regulated for safety and labeling — cosmetics are never "FDA approved." As an injectable/subcutaneous product sold "for research use only," it has no FDA marketing authorization for human use. There is no approved GHK-Cu prescription product. See our legal status guide for the broader picture.

503A compounding status: GHK-Cu (except for injectable routes of administration) is currently in 503A Category 1 — the FDA's "under evaluation" bucket. Per the FDA's own list: GHK-Cu "was removed from category 1 on April 22, 2026, because the nominations for GHK-Cu were withdrawn by the nominators. On May 5, 2026, one of those nominators clarified that it intended to withdraw only its nomination of the injectable route of administration with respect to GHK-Cu and would like to retain its nomination for GHK-Cu for non-injectable routes of administration. GHK-Cu (except for injectable routes of administration) will be added back to category 1." In practice, this means the FDA does not currently intend to take enforcement action against pharmacies compounding non-injectable GHK-Cu while it completes its evaluation — that is enforcement discretion, not approval or authorization to compound. The injectable route is explicitly excluded from Category 1 and is the subject of the separate PCAC advisory review expected before the end of February 2027 (see our FDA regulations breakdown).

Takeaway first: GHK-Cu appears to do two things at once — it hand-delivers copper (a metal your repair enzymes depend on) into tissue, and it acts as a signaling molecule that nudges cells toward building new collagen and matrix rather than breaking tissue down. Most of what follows is established in cell cultures and animals; the human mechanistic data is thinner.

1. Copper delivery and enzyme support

Copper is a required cofactor for several repair enzymes, including lysyl oxidase (which cross-links collagen and elastin so skin has strength and spring), superoxide dismutase (an antioxidant defense enzyme), and cytochrome c oxidase (part of cellular energy production). GHK binds copper tightly and can shuttle it to where these enzymes work. This is a well-accepted biochemical role and is part of why the molecule is blue-green — that color is the copper.

2. Collagen, glycosaminoglycan, and decorin synthesis

Review-level and in-vitro evidence indicates GHK-Cu stimulates production of collagen and of glycosaminoglycans such as dermatan sulfate and chondroitin sulfate, along with decorin — a small proteoglycan that helps organize collagen fibrils so the resulting tissue is orderly rather than scar-like.^[1] It also appears to modulate matrix metalloproteinases (enzymes that remodel and can degrade tissue) and their inhibitors, TIMP-1 and TIMP-2 — shifting the balance toward controlled remodeling.

3. Epidermal renewal (skin cell proliferation)

In a controlled cell-culture and skin-equivalent study, copper-GHK increased keratinocyte (skin cell) proliferation and raised markers of active renewal — PCNA and p63 positivity — while increasing integrin alpha6/beta1 expression.^[4] This is a plausible mechanism for how topical GHK-Cu might support epidermal turnover. Important caveat: this is laboratory data on cells and reconstructed skin, not a measured clinical outcome in living people.

4. Wound healing and connective-tissue accumulation (animal data)

The most quantitatively striking mechanism evidence comes from rats. When GHK-Cu was injected into experimental wound chambers, wound collagen content rose in a concentration-dependent way — reaching 396% of matched controls at day 18 and 538% at day 22, with increases in both Type I and Type III collagen.^[3] Those are large effects, but they are in rats, with the peptide delivered directly into the wound. They tell us the biology is real in animals; they do not establish the same magnitude in human skin.

5. Anti-inflammatory and broader regenerative signaling

Pickart and Margolina's 2018 review compiles a wider set of proposed actions: promoting angiogenesis (new blood vessel growth) and nerve outgrowth, supporting elastin and matrix synthesis, dampening inflammatory signaling, and engaging DNA-repair and proteasome (cellular cleanup) pathways.^[2] This is a review synthesizing many preclinical sources — useful for understanding the proposed mechanism, but not a substitute for controlled human trials.

Here is the honest hierarchy: GHK-Cu's benefits are best supported in the lab and in animals, moderately supported by cosmetic use and review articles for topical skin, and weakly supported (essentially untested in controlled human trials) for injectable/systemic uses. We walk through each claim with its mechanism, the population actually studied, the effect size where one exists, and the limitation.

Skin rejuvenation and anti-aging

Claim: Topical GHK-Cu improves skin firmness, texture, and the appearance of fine lines. Mechanism: stimulation of collagen, glycosaminoglycans, and decorin, plus support for epidermal renewal.^[1][4] Population and evidence: this is the most commercially developed use, and copper peptides have decades of cosmetic use behind them — but the widely quoted "70% more collagen in 12 weeks" and "outperforms retinol and vitamin C" statements trace back to a 2002 American Academy of Dermatology conference abstract (Leyden) that is not cleanly indexed as a peer-reviewed primary source. We therefore do not present those figures as established fact. Effect size: not reliably quantified in independent, PubMed-indexed controlled human trials. Limitation, stated plainly: the single best-controlled human skin study on GHK-Cu — a study of 13 patients using topical copper-tripeptide on CO2 laser-resurfaced skin — found no significant reduction in post-treatment redness versus control.^[5] A null result in a small trial does not prove GHK-Cu is useless for skin, but it is a strong reason to keep expectations modest and to distrust dramatic marketing numbers.

Wound healing

Claim: GHK-Cu accelerates wound repair and yields more organized, less scar-like tissue. Mechanism: increased collagen deposition, angiogenesis, immune-cell recruitment, and decorin-guided collagen organization. Population and effect size: in rat wound chambers, injected GHK-Cu raised wound collagen to 396% (day 18) and 538% (day 22) of controls, with more Type I and Type III collagen.^[3] Limitation: this is animal data with direct-to-wound delivery. It is genuinely strong preclinical evidence, but it is not a human clinical outcome, and topical products applied to intact skin behave very differently from a peptide injected into an open wound.

Hair growth

Claim: GHK-Cu supports hair by enlarging follicles and improving follicular blood supply. Mechanism: proposed angiogenesis around follicles plus the general pro-repair signaling profile. Population and effect size: the supporting data is largely preclinical and mechanistic; there is no large, well-controlled human trial establishing an effect size for pattern hair loss. Limitation: claims of "comparable to minoxidil" are not backed by head-to-head human trials we can cite here — treat hair growth as an experimental, poorly quantified use. See the peptides for hair growth guide for the broader landscape.

Anti-fibrotic and other systemic ideas

Claim: GHK-Cu may reduce excessive scarring/fibrosis and has broad tissue-protective potential. Mechanism: the gene-expression pattern in review analyses downregulates some fibrosis- and inflammation-associated genes.^[2] Population and effect size: no controlled human trials for fibrosis, pulmonary or hepatic, have been conducted. Limitation: this is a hypothesis generated from bioinformatics and animal work — interesting, unproven in people.

Bottom line for beginners: the strongest evidence supports topical GHK-Cu as a reasonable, generally well-tolerated cosmetic ingredient with plausible collagen-supporting biology and modest, hard-to-quantify real-world benefit. Everything beyond that — injectable anti-aging, hair regrowth, systemic repair — is under-studied in humans and should be approached with appropriate skepticism.

Read this first: There is no single "correct" GHK-Cu dose, and the doses below are research and cosmetic ranges reported in the literature and the research community — not medical recommendations. The topical route has by far the most evidence and the least risk. Injectable protocols come largely from the research-peptide community and have very little controlled human data behind them.

Dosage by route

Route	Dose	Frequency	Primary application	Cycle
Topical (cream / serum)	1–3% concentration	1–2x daily	Skin anti-aging, fine lines, post-procedure recovery	Ongoing / no cycling
Topical (high-concentration spot treatment)	up to ~5%	Once daily	Scarring, deeper wrinkles	8–12 weeks
Subcutaneous	200–500 mcg daily	Once daily	Systemic / repair support (low human evidence)	4–8 week cycles
Intradermal (scalp)	50–200 mcg per session	1–2x weekly	Follicle stimulation (experimental)	3–6 months
Microneedling adjunct	Applied during / after needling	Per session, 2–4 weeks apart	Scarring, photoaging, scalp	4–6 sessions

Body weight is generally not a primary dosing variable for GHK-Cu — published protocols use fixed ranges rather than mcg-per-kg. Clinical skin literature centers on topical concentrations; systemic subcutaneous ranges come from the research community, not controlled trials.

Topical protocol (recommended for most people)

Topical GHK-Cu has the largest evidence base and the lowest risk. Practical parameters used in cosmetic products and studies:

• Concentration: 1–3% is the typical cosmetic range; some studies used up to ~5%.
• Vehicle: a stable emulsion or serum. Avoid very low-pH vehicles (below about pH 5), which destabilize the copper complex.
• Application: apply to clean, dry skin; layer under heavier creams. Most people tolerate twice-daily use.
• Sun protection: use SPF 30+ during the day, especially in the first weeks.
• Time to effect: if a benefit appears, texture and tone changes typically show over 4–8 weeks, with any deeper changes accumulating over 12+ weeks. Set modest expectations given the mixed human evidence.

For a layered routine, see the GLOW peptide blend.

Subcutaneous reconstitution — with a worked example

Injectable GHK-Cu comes as a lyophilized (freeze-dried) powder, usually in 50 mg or 100 mg vials. The blue-green color after mixing is normal and signals an intact copper complex; loss of color suggests degradation.

Worked example. Take a 50 mg vial and add 5 mL of bacteriostatic water. That gives:

• 50 mg ÷ 5 mL = 10 mg/mL, which is 10,000 mcg per mL.
• To draw a 250 mcg dose: 250 ÷ 10,000 = 0.025 mL. On a standard 100-unit insulin syringe, 1 mL = 100 units, so 0.025 mL = 2.5 units.
• To draw a 500 mcg dose: 0.05 mL = 5 units.

Other common mixes:

• 50 mg + 2 mL = 25 mg/mL (25,000 mcg/mL); 250 mcg = 0.01 mL = 1 unit. Very small volume — measure carefully.
• 100 mg + 5 mL = 20 mg/mL (20,000 mcg/mL); 500 mcg = 0.025 mL = 2.5 units.

Use the peptide calculator for exact volumes, and the reconstitution guide for step-by-step preparation. Inject subcutaneously into the abdomen, thigh, or upper arm and rotate sites; see the injection technique guide.

Stability, compatibility, and storage

• pH: most stable around pH 6.5–7.5. Do not layer immediately with low-pH actives (L-ascorbic acid vitamin C below ~pH 4, AHAs) — the copper complex breaks down.
• Oxidizers: never combine with benzoyl peroxide; it destroys the peptide.
• Light: UV degrades it — use opaque or amber packaging.
• Temperature: store lyophilized vials at -20°C or 2–8°C; refrigerate reconstituted solution at 2–8°C and use within about 28–30 days.

See the peptide storage guide for details.

Cycle length

Topical GHK-Cu has been used continuously for years in cosmetics with no documented tolerance issue — no cycling is required. Systemic protocols are typically run in 4–8 week cycles because the long-term effects of sustained above-normal serum GHK-Cu in humans are simply not characterized.

Takeaway: Because GHK-Cu is a molecule your own body makes, its topical use has a strong, decades-long safety record, and the most common issues are minor and local. Injectable use has far less human safety data. The one group that must firmly avoid systemic GHK-Cu is people with copper-accumulation disorders such as Wilson's disease.

Topical side effects (grouped by frequency)

Effect	Frequency	Onset	What to do
Mild stinging / tingling on application	Common (5–15%)	Immediate	Usually resolves in minutes and adapts over 1–2 weeks
Transient blue-green skin tint	Common above ~3%	Immediate	Cosmetic only; washes off, not permanent
Contact/allergic dermatitis	Uncommon (<2%)	1–7 days	Discontinue; patch-test first if you have a metal-allergy history
Increased photosensitivity	Rare, anecdotal	Variable	Use SPF; avoid stacking with retinoids early on

The blue-green color is copper(II) coordinated with the peptide — a normal property of the molecule, not a sign of irritation or contamination.

Subcutaneous and intradermal side effects

Injectable GHK-Cu has substantially less human safety data than topical use, and the available literature is small and short. Reported effects:

• Injection-site reactions: redness, mild swelling, or bruising; usually resolve in 24–72 hours.
• Transient flushing: brief facial flushing in some users; typically resolves within about 30 minutes.
• Headache or mild fatigue: occasionally in the first week; usually self-limited.
• Sterile abscess: rare, associated with poor technique or contaminated reconstitution — see the injection technique guide.

No serious organ-level adverse events have been reported in the small published literature on GHK-Cu dosing — but the sample sizes are tiny, so absence of reports is not the same as proof of safety.

Copper load and Wilson's disease

Each GHK-Cu complex carries one copper ion. Subcutaneous protocols of 200–500 mcg deliver only single-digit-to-low-double-digit micrograms of elemental copper per dose — well under the adult copper RDA of about 900 mcg/day and far under the Institute of Medicine tolerable upper intake level of 10,000 mcg/day.^[6] So for an adult with normal copper metabolism, copper toxicity from research-dose GHK-Cu is highly unlikely. The exception is critical: Wilson's disease and other copper-accumulation disorders are absolute contraindications for systemic use, because even small extra copper can worsen dangerous accumulation. Idiopathic copper toxicosis, active hepatic copper accumulation, and known copper allergy (e.g., reactions to copper IUDs) also warrant avoidance.

Drug and skincare interactions

• Low-pH vitamin C (L-ascorbic acid): chemically reduces the copper and breaks the complex — use on separate routines or hours apart.
• Benzoyl peroxide: oxidizes and destroys the peptide — do not co-apply.
• Retinoids, AHAs/BHAs: not necessarily incompatible but can compound irritation or affect stability — introduce one active at a time.
• Wilson's disease therapies (penicillamine, trientine, zinc): systemic GHK-Cu opposes their purpose — contraindicated.

Special populations

• Pregnancy and breastfeeding: no controlled human data; copper crosses the placenta. Avoid systemic GHK-Cu; consult an obstetrician before any active skincare.
• Children and adolescents: no pediatric safety data — not recommended outside specialist supervision.
• Active cancer: because GHK-Cu modulates repair and angiogenesis pathways, discuss with your oncologist before any use.

What to do if you react

• Mild topical irritation: drop to alternate-day use or a lower concentration, or pause 48 hours and resume less often.
• Rash, blistering, or persistent redness: stop, treat with topical hydrocortisone if needed, and see a dermatologist if it lasts beyond 72 hours.
• Injection-site reaction beyond 5 days: evaluate for infection or sterile abscess; stop and seek care.
• Unexplained fatigue, abdominal pain, or neurological symptoms during systemic use: stop and screen for copper accumulation (serum ceruloplasmin, 24-hour urine copper).

Takeaway: Because GHK-Cu is unregulated as an injectable and lightly regulated as a cosmetic, product quality varies widely between suppliers. For most compounds, poor quality is a bigger practical risk than the molecule itself.

Two very different regulatory lanes

• Topical cosmetic (Copper Tripeptide-1): sold legally as a cosmetic ingredient. Cosmetics are regulated for safety and labeling in the US — they are not "FDA approved." Reputable brands will list concentration and keep the product in opaque, stable packaging.
• Injectable "research use only": not an FDA-approved drug and has no marketing authorization for human use. It is sold with "not for human consumption" labeling.

See our legal status guide for how these lanes fit the broader peptide regulatory landscape.

Quality indicators to look for

• Third-party Certificate of Analysis (COA): HPLC purity (look for ~98%+) plus mass-spectrometry identity confirmation, referencing the specific lot you are buying — not a generic sample COA.
• Endotoxin testing (LAL): important for any injectable product.
• Proper form and packaging: lyophilized powder in sealed, light-protected vials; the intact reconstituted solution should be blue-green.

Red flags

• No COA, or a COA from the seller rather than an independent lab
• Pre-reconstituted liquid (shorter shelf life, higher contamination risk)
• Prices far below the market average
• Explicit "for human use" or health-claim labeling on a research product

For handling once you have a product, see the peptide storage guide.

GHK-Cu is unusual among research peptides in being available both as a low-risk topical and as an injectable. For most people asking "which is right for me," the honest answer is: if your goal is skin, the topical route is the sensible, evidence-supported, low-risk starting point.

Factor	Topical	Injectable (SC)
Primary use	Skin anti-aging, surface support	Systemic / experimental repair, hair
Penetration	Epidermis and upper dermis	Systemic distribution
Evidence level	Decades of cosmetic use + review support; one null controlled trial	Minimal controlled human data
Risk	Low; mostly minor local irritation	Higher; injection risks and less-characterized safety
Convenience	Daily application, no preparation	Reconstitution and injection required

For purely cosmetic skin concerns, topical GHK-Cu is the most accessible and best-supported option. Injectable use is experimental, aimed at systemic effects, and carries less human safety data — approach it with that context in mind.